@article{ref1,
title="Review and critique of the Institute of Medicine report "the future of drug safety"",
journal="Clinical pharmacology and therapeutics",
year="2007",
author="Benet, L. Z.",
volume="81",
number="2",
pages="158-161",
abstract="In September 2006 an Institute of Medicine (IOM) ad hoc committee on the Assessment of the US Drug Safety System released its report entitled &quot;The Future of Drug Safety: Promoting and Protecting the Health of the Public&quot;. The committee's report includes 25 recommendations that &quot;will bring the strengths of the preapproval process (data, regulatory authority, organizational function and capabilities, and resources) to the postapproval phase in order to fulfill a lifecycle approach to the study, regulation, and communication about the risks and benefits of drugs.&quot; Copies of the report are available from the National Academies Press (800-624-6242), and the full text is available at http://www.nap.edu.<p /><p>Language: en</p>",
language="en",
issn="0009-9236",
doi="10.1038/sj.clpt.6100083",
url="http://dx.doi.org/10.1038/sj.clpt.6100083"
}